US regulatory status: approved. Molecular target: Carbonic anhydrase 1.
- Target
- Carbonic anhydrase 1
- Mechanism
- Carbonic anhydrase XII inhibitor
biotech · Recurrent Pericarditis · Acute Myocarditis · CRDL
Cardiol Therapeutics
Cardiol Therapeutics drug portfolio — 31 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
2265 Upper Middle Rd E, Suite 602, Greater Toronto Area, Ontario L6H 0G5, CA HQ
2017 Founded
27 Employees
Public company Type
CRDL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2265 Upper Middle Rd E, Suite 602, Greater Toronto Area, Ontario L6H 0G5, CA
- Founded
- 2017
- Employees
- 27
- Programs
- 11
- Drugs
- 31
- Patents
- 15
Cardiol Therapeutics pipeline
Portfolio lens on 31 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Cardiol Therapeutics drug portfolio — 31 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
cannabidiol
Nervous system (N03)US regulatory status: approved. Molecular target: Cannabinoid receptor 1.
- Target
- Cannabinoid receptor 1
- Mechanism
- Cannabinoid CB1 receptor negative allosteric modulator
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor beta antagonist
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Cardiol Therapeutics's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Cardiol Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Essential for cellular homeostasis.
- Mechanism
- Essential for cellular homeostasis
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.
-
prasugrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Cardiol Therapeutics's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
US regulatory status: approved. Molecular target: P2Y purinoceptor 12.
- Target
- P2Y purinoceptor 12
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
propranolol
Cardiovascular system (C07)Cardiovascular system (C07) compound in Cardiol Therapeutics's portfolio. Mechanism: Beta-1 adrenergic receptor antagonist.
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.
-
sildenafil
Genito-urinary system and sex hormones (G04)Genito-urinary system and sex hormones (G04) compound in Cardiol Therapeutics's portfolio. Mechanism: Phosphodiesterase 5A inhibitor.
- Mechanism
- Phosphodiesterase 5A inhibitor
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.
-
ticagrelor
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: P2Y purinoceptor 12.
- Target
- P2Y purinoceptor 12
- Mechanism
- Purinergic receptor P2Y12 negative allosteric modulator
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.
-
Development asset linked to Cardiol Therapeutics in public FDA and regional records.